Patents by Inventor Morten Lindow

Morten Lindow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20240035032
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: February 27, 2023
    Publication date: February 1, 2024
    Applicant: Hoffmann-La roche Inc.
    Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
  • Oligomers and oligomer conjugates
    Patent number: 11591598
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20210054381
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: September 4, 2020
    Publication date: February 25, 2021
    Applicant: Hoffmann-La roche Inc.
    Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
  • Oligomers and oligomer conjugates
    Patent number: 10767181
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20200024605
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: August 2, 2019
    Publication date: January 23, 2020
    Applicant: Hoffmann-La roche Inc.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • Micromirs
    Patent number: 10450564
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 22, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Oligomers and oligomer conjugates
    Patent number: 10421967
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 24, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • THERAPEUTIC OLIGONUCLEOTIDES CAPTURE AND DETECTION
    Publication number: 20190284621
    Abstract: The present invention relates to the detection of therapeutic modified oligonucleotides in biological samples and an adaptor oligonucleotide (capture probe) which enables a quantitative PCR based detection method and the sequencing of modified oligonucleotides. The invention provides novel adaptor probes for use in detecting therapeutic oligonucleotides and for in vivo discovery of preferred therapeutic oligonucleotide sequences.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Morten LINDOW, Jonas VIKESAA
  • Poly oligomer compound with biocleavable conjugates
    Patent number: 10358643
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 23, 2019
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Morten Lindow, Jacob Ravn, Mark Turner
  • MICROMIRS
    Publication number: 20180201928
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 19, 2018
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES
    Publication number: 20170349896
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 7, 2017
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Morten Lindow, Jacob Ravn, Mark Tumer
  • MICROMIRs
    Patent number: 9790493
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 17, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE
    Publication number: 20160108396
    Abstract: The disclosure relates to oligomers capable of targeting RNA expressed from the human C9ORF72 gene containing a pathogenic hexanucleotide repeat expansion. Such oligomers are useful for, among other things, reducing or eliminating C9ORF72 RNA and/or proteins translated therefrom, and treating or preventing diseases or disorders caused by, or associated with, hexanucleotide repeat expansion, including familial frontotemporal dementia (FTD) and familial amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: August 14, 2015
    Publication date: April 21, 2016
    Inventors: Mads Aaboe Jensen, Morten Lindow
  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20160010093
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: May 15, 2015
    Publication date: January 14, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
  • LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
    Publication number: 20150368642
    Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 24, 2015
    Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW
  • MICROMIRs
    Publication number: 20150299699
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 22, 2015
    Inventors: Susanna OBAD, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • MicromiRs
    Patent number: 8906871
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: December 9, 2014
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • MicroRNAs
    Patent number: 8288356
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • NOVEL HUMAN MICRORNAS ASSOCIATED WITH CANCER
    Publication number: 20120184603
    Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
    Type: Application
    Filed: March 30, 2012
    Publication date: July 19, 2012
    Applicant: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
  • Human microRNAs associated with cancer
    Patent number: 8188255
    Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: May 29, 2012
    Assignee: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde